How wonderful for prime minister Jean Castex to begin his press conference by applauding residents and politicians in the Alpes-Maritimes for all of their efforts over the past three weekends, the result of which has significantly brought down the incidence rate, and then to announce the department, along with 15 others, will begin a 4-week minimum confinement starting Friday, March 19, at midnight.
This impacts the 8 departments in Ile-de-France, 5 departments in Hauts-de-France and the Seine-Maritime, Eure and Alpes-Maritimes.
You know the drill by now: all schools will remain open, as will essential services and businesses (which includes book and music stores).
For sports, outings, walking the dog and such, you still need an attestation but you can go up to 10km and there is no time limit.
Read also: Curfew And Other Covid Measures Extended In Monaco
The nationwide curfew has been pushed back an hour, and will start at 7 pm.
Interregional travel between confined departments will be prohibited.
With contaminations resulting from the workplace making up 29% of all cases, remote working maximum will go into effect, for a minimum of 4 of 5 days of the week.
In Ile de France, cases have shot up 23.6% in one week as France’s third wave is driven by the British strain found in 75% of all cases. In France, one person every four minutes is admitted into ICU, as the number reaches 4,260. Patients are younger, between 40 and 60, and in better health than the previous waves. Additionally, they are staying longer in intensive care.
As the European Medicines Agency has given the green light for the continued use of the Oxford/AstraZeneca vaccine, Prime minister Castex will be getting vaccinated with it tomorrow on TV.
“This is a safe and effective vaccine, its benefits in protecting people from Covid-19 with the associated risks of death and hospitalisation outweigh the possible risks,” the commission reported at a press conference earlier today.
“The committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolitic events or blood clots.”